Characterising the Tumour Suppression Function of Folliculin

Total Page:16

File Type:pdf, Size:1020Kb

Characterising the Tumour Suppression Function of Folliculin Characterising the Tumour Suppression Function of Folliculin Rachael Preston 0740708 Thesis submitted for the degree of Doctor of Philosophy 1 Abstract Birt–Hogg–Dubé (BHD) syndrome is a rare inherited autosomal dominant disorder first described by Birt, Hogg and Dube in 1977 (Birt et al,. 1977). BHD affects approximately 100 families worldwide. Approximately one third of diagnosed BHD patients also develop renal cell carcinoma (RCC) (Schmidt et al., 2005). BHD arises as a result of loss of function of the Folliculin protein expressed from the BHD gene, suggesting than Folliculin serves as a tumour suppressor (Vocke et al., 2005). Although it is considered that FLCN represses cell growth, the role that FLCN plays in cancer progression and/or initiation is currently unresolved. It has been observed that tumours taken from BHD patients have reduced levels of mitochondria (Yang et al., 2008). Previous studies have also suggested that aberrant levels of mTOR activity are observed in Folliculin-deficient cell lines (Baba et al., 2006; Baba et al., 2008). Aberrant levels of mTORC1 activity have been associated with increased levels of Hypoxia inducible factor transcriptional activity, decreased autophagic activity (Land and Tee, 2007; Hands et al., 2009). There are several genes within the mTOR pathways which act as Tumour Suppressors. Mutations within these genes result in inherited genetic disorders, including Tuberous, Sclerosis complex (TSC). Loss of function of TSC1/TSC2 results in TSC which is clinically similar to BHD (Gomez et al., 1999). Arbarrant levels of mitochondrial biogeneisis and HIF activity have been observed in cells deficient in TSC1 ad TSC2 (Land and Tee, 2007; Chen et al., 2008). Increased levels of mTORC1 activity have also been shown to result in decreased levels of autophagic activity in TSC2 deficient cells (Parkhitko et al., 2011). In order to characterise the tumour suppression function of Folliculin, the effects of loss of function of Folliculin on mitochondrial biogenesis and mitochondrial function, hypoxia inducible factor (HIF) transcriptional activity, and autophagic activity were investigated using multiple cell lines. The results from this study suggest that loss of function of FLCN results in increased production of ROS species. This leads to compromised mitochondrial membrane potential and decreased ATP production as a result of increased expression of uncoupling proteins in order to try and reduce the increased levels of ROS. FLCN is also phosphorylated at multiple residues by both mTORC1 and AMPK and activity of both mTORC1 and AMPK is increased in response to the depleted ATP levels as a result of increased UCP production in response to the increased ROS production observed upon loss of functional FLCN. This results in increased levels of mitochondrial biogenesis and increased levels of glycolytic activity via increased activation of HIFα proteins in order to compensate for this energy deficit. Furthermore, it appears that both mTORC1 and AMPK could drive HIF transcription and mitochondrial biogenesis through modulation of FLCN phosphorylation. ULK-mediated autophagy also appears to be upregulated upon loss of functional FLCN, possibly as a result of the increased levels of AMPK activation in order to provide a protection for these cells. This may be via the catabolising the dysfunctional mitochondria observed in cells upon loss of BHD, a process which may be exploited as a potential therapeutic target for BHD patients. Further investigations into these cellular processes may also provide clues to potential therapeutic targets for treatment of BHD patients. 2 Contents 1 Introduction ....................................................................................................................................... 11 1.1 Birt-Hogg-Dube Syndrome. ......................................................................................................... 11 1.2 Folliculin ...................................................................................................................................... 11 1.3 Animal models of BHD ................................................................................................................ 12 1.3.1 The Rat model of BHD .......................................................................................................... 12 1.3.2 The Dog model of BHD ......................................................................................................... 12 1.3.3 The Drosophila melanogaster model of BHD....................................................................... 13 1.3.4 The S. pombe model of BHD ................................................................................................ 13 1.3.5 Mouse models of BHD ......................................................................................................... 13 1.4 The UOK257 cell line ................................................................................................................... 14 1.5 Genetic studies of BHD ............................................................................................................... 15 1.5.1 Mutations of the BHD gene in BHD patients ....................................................................... 15 1.5.2 Geneotype – phenotype correlation studies in BHD patients ............................................ 16 1.6 Signalling pathways which are regulated by FLCN ...................................................................... 20 1.6.1 The Raf-MEK-Erk pathway ................................................................................................... 20 1.6.2 JAK/STAT signalling .............................................................................................................. 20 1.6.3 TGF-β signalling and transcriptional control ........................................................................ 21 1.7 FLCN-binding proteins ................................................................................................................. 21 1.8 Tumour suppressors ................................................................................................................... 22 1.8.1 Tumour suppressors and apoptosis ..................................................................................... 22 1.8.2 Tumour suppressors and cellular senescence ..................................................................... 23 1.9 The mTOR signalling pathway. .................................................................................................... 24 1.10 mTOR signalling and cancer. ..................................................................................................... 28 1.11 Tumour suppressor genes within the mTOR pathway ............................................................. 29 1.11.1 Tuberous Sclerosis Complex. ............................................................................................. 30 1.11.5 Von-Hippel-Lindau disease ................................................................................................ 31 1.12 Constitutive activation of mTORC1 may also contribute to the development of tumours in BHD patients. .................................................................................................................................... 32 1.13 FLCN is differentially phosphorylated by AMPK and mTOR. .................................................... 33 1.14 AMPK and cancer ...................................................................................................................... 35 1.15 Both AMPK and mTOR positively regulate mitochondrial biogenesis ...................................... 35 1.16 Both AMPK and mTOR positively regulate Hypoxia Inducible Factor transcriptional activity . 36 3 1.17 AMPK activation results in increased autophagic activity. ....................................................... 37 1.18 Renal cell carcinomas. ............................................................................................................... 40 1.18.1 Clear cell renal cell carcinomas .......................................................................................... 40 1.18.2 Chromophobe renal cell carcinomas. .............................................................................. 40 1.18.3 Papillary renal cell carcinomas ........................................................................................... 40 1.18.4 Oncocytomas ..................................................................................................................... 41 1.18.5 Renal cell carcinoma syndromes, mitochondrial dysfunction and aberrant HIF signalling. ...................................................................................................................................................... 41 1.19 Cyst formation .......................................................................................................................... 42 1.19.1 Polycystic kidney disease ................................................................................................... 42 1.19.1 Ciliopathy and renal cyst formation ................................................................................... 43 1.19.2 mTOR signalling and cystogenesis. .................................................................................... 43 1.20 Aims and Objectives of this Project .......................................................................................... 44 2 The effect
Recommended publications
  • Novel Folliculin Gene Mutations in Polish Patients with Birt–Hogg–Dubé Syndrome Elżbieta Radzikowska1*, Urszula Lechowicz2, Jolanta Winek3 and Lucyna Opoka4
    Radzikowska et al. Orphanet J Rare Dis (2021) 16:302 https://doi.org/10.1186/s13023-021-01931-0 RESEARCH Open Access Novel folliculin gene mutations in Polish patients with Birt–Hogg–Dubé syndrome Elżbieta Radzikowska1*, Urszula Lechowicz2, Jolanta Winek3 and Lucyna Opoka4 Abstract Background: Birt–Hogg–Dubé syndrome (BHDS) is a rare, autosomal dominant, inherited disease caused by muta- tions in the folliculin gene (FLCN). The disease is characterised by skin lesions (fbrofolliculomas, trichodiscomas, acrochordons), pulmonary cysts with pneumothoraces and renal tumours. We present the features of Polish patients with BHDS. Materials and methods: The frst case of BHDS in Poland was diagnosed in 2016. Since then, 15 cases from 10 fami- lies have been identifed. Thirteen patients were confrmed via direct FLCN sequencing, and two according to their characteristic clinical and radiological presentations. Results: BHDS was diagnosed in 15 cases (13 women and 2 men) from 10 families. The mean ages at the time of frst pneumothorax and diagnosis were 38.4 13.9 and 47.7 13 years, respectively. Five patients (33%) were ex- smokers (2.1 1.37 packyears), and 10 (67%)± had never smoked± cigarettes. Twelve patients (83%) had a history of recurrent symptomatic± pneumothorax. Three patients had small, asymptomatic pneumothoraces, which were only detected upon computed tomography examination. All patients had multiple bilateral pulmonary cysts, distributed predominantly in the lower and middle, peripheral, and subpleural regions of the lungs. Generally, patients exhibited preserved lung function. Skin lesions were seen in four patients (27%), one patient had renal angiomyolipoma, and one had bilateral renal cancer.
    [Show full text]
  • Mitochondrial Transcription Factor a Promotes DNA Strand Cleavage at Abasic Sites
    Mitochondrial transcription factor A promotes DNA strand cleavage at abasic sites Wenyan Xu (许文彦)a,1, Riley M. Boyda,1, Maya O. Treea, Faris Samkaria, and Linlin Zhaoa,b,2,3 aDepartment of Chemistry and Biochemistry, Central Michigan University, Mount Pleasant, MI 48859; and bBiochemistry, Cellular, and Molecular Biology Graduate Program, Central Michigan University, Mount Pleasant, MI 48859 Edited by Rafael Radi, Universidad de la Republica, Montevideo, Uruguay, and approved July 18, 2019 (received for review July 2, 2019) In higher eukaryotic cells, mitochondria are essential subcellular damage in cells (13, 14). Within mitochondria, AP lesions are organelles for energy production, cell signaling, and the biosynthesis also abundant and can number in the hundreds per cell, con- of biomolecules. The mitochondrial DNA (mtDNA) genome is in- sidering their steady-state level (0.2 to 3 AP sites per 105 bp) (15, dispensable for mitochondrial function because it encodes protein 16) and the number of mtDNA copies per cell (∼1,000) (17). subunits of the electron transport chain and a full set of transfer and Importantly, AP sites are chemically labile and reactive and can ribosomal RNAs. MtDNA degradation has emerged as an essential lead to secondary DNA damage such as DNA single-strand quality control measure to maintain mtDNA and to cope with mtDNA breaks (SSBs), DNA–DNA interstrand cross-links, and DNA– damage resulting from endogenous and environmental factors. protein cross-links (DPCs) (18–23). If not repaired, AP sites Among all types of DNA damage known, abasic (AP) sites, sourced and their derivatives are mutagenic in the nuclear genome (24– from base excision repair and spontaneous base loss, are the most 26); however, the understanding of the biological consequence of abundant endogenous DNA lesions in cells.
    [Show full text]
  • Transcription from the Second Heavy-Strand Promoter of Human Mtdna Is Repressed by Transcription Factor a in Vitro
    Transcription from the second heavy-strand promoter of human mtDNA is repressed by transcription factor A in vitro Maria F. Lodeiroa, Akira Uchidaa, Megan Bestwickb, Ibrahim M. Moustafaa, Jamie J. Arnolda, Gerald S. Shadelb,c, and Craig E. Camerona,1 aDepartment of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802; bDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06520; and cDepartment of Genetics, Yale University School of Medicine, New Haven, CT 06520 Edited* by Douglas C. Wallace, Center for Mitochondrial and Epigenomic Medicine (CMEM), Children’s Hospital of Philadelphia, Philadelphia, PA, and approved March 8, 2012 (received for review November 15, 2011) Cell-based studies support the existence of two promoters on the factor B2 (TFB2M). The long-standing paradigm was that TFAM heavy strand of mtDNA: heavy-strand promoter 1 (HSP1) and HSP2. binds to a site in the promoter upstream of the transcription start However, transcription from HSP2 has been reported only once in site and recruits a complex POLRMT/TFB2M by an interaction of a cell-free system, and never when recombinant proteins have been the carboxyl-terminal tail of TFAM with TFB2M (3). However, we used. Here, we document transcription from HSP2 using an in vitro recently showed that basal mitochondrial transcription is not ab- system of defined composition. An oligonucleotide template repre- solutely dependent on TFAM (4). This observation suggested that senting positions 596–685 of mtDNA was sufficient to observe tran- the two-component transcription system found in lower eukaryotes scription by the human mtRNA polymerase (POLRMT) that was had acquired an additional layer of regulation in mammals that is absolutely dependent on mitochondrial transcription factor B2 mediated by TFAM (4).
    [Show full text]
  • Mitochondrial Dysfunction in Sepsis Is Associated with Diminished
    www.nature.com/scientificreports OPEN Mitochondrial dysfunction in sepsis is associated with diminished intramitochondrial TFAM despite its increased cellular expression Tim Rahmel 1*, Britta Marko1, Hartmuth Nowak1, Lars Bergmann1, Patrick Thon1, Katharina Rump1, Sebastian Kreimendahl2, Joachim Rassow2, Jürgen Peters3, Mervyn Singer4, Michael Adamzik1,5 & Björn Koos1,5 Sepsis is characterized by a dysregulated immune response, metabolic derangements and bioenergetic failure. These alterations are closely associated with a profound and persisting mitochondrial dysfunction. This however occurs despite increased expression of the nuclear-encoded transcription factor A (TFAM) that normally supports mitochondrial biogenesis and functional recovery. Since this paradox may relate to an altered intracellular distribution of TFAM in sepsis, we tested the hypothesis that enhanced extramitochondrial TFAM expression does not translate into increased intramitochondrial TFAM abundance. Accordingly, we prospectively analyzed PBMCs both from septic patients (n = 10) and lipopolysaccharide stimulated PBMCs from healthy volunteers (n = 20). Extramitochondrial TFAM protein expression in sepsis patients was 1.8-fold greater compared to controls (p = 0.001), whereas intramitochondrial TFAM abundance was approximate 80% less (p < 0.001). This was accompanied by lower mitochondrial DNA copy numbers (p < 0.001), mtND1 expression (p < 0.001) and cellular ATP content (p < 0.001) in sepsis patients. These fndings were mirrored in lipopolysaccharide stimulated PBMCs taken from healthy volunteers. Furthermore, TFAM- TFB2M protein interaction within the human mitochondrial core transcription initiation complex, was 74% lower in septic patients (p < 0.001). In conclusion, our fndings, which demonstrate a diminished mitochondrial TFAM abundance in sepsis and endotoxemia, may help to explain the paradox of lacking bioenergetic recovery despite enhanced TFAM expression.
    [Show full text]
  • Clinical and Genetic Characteristics of Chinese Patients with Birt-Hogg
    Liu et al. Orphanet Journal of Rare Diseases (2017) 12:104 DOI 10.1186/s13023-017-0656-7 RESEARCH Open Access Clinical and genetic characteristics of chinese patients with Birt-Hogg-Dubé syndrome Yaping Liu1†, Zhiyan Xu2†, Ruie Feng3, Yongzhong Zhan4,5, Jun Wang4, Guozhen Li4, Xue Li4, Weihong Zhang6, Xiaowen Hu7, Xinlun Tian4*†, Kai-Feng Xu4† and Xue Zhang1† Abstract Background: Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant disorder, the main manifestations of which are fibrofolliculomas, renal tumors, pulmonary cysts and recurrent pneumothorax. The known causative gene for BHD syndrome is the folliculin (FLCN) gene on chromosome 17p11.2. Studies of the FLCN mutation for BHD syndrome are less prevalent in Chinese populations than in Caucasian populations. Our study aims to investigate the genotype spectrum in a group of Chinese patients with BHD. Methods: We enrolled 51 patients with symptoms highly suggestive of BHD from January 2014 to February 2017. The FLCN gene was examined using PCR and Sanger sequencing in every patient, for those whose Sanger sequencing showed negative mutation results, multiplex ligation-dependent probe amplification (MLPA) testing was conducted to detect any losses of large segments. Main results: Among the 51 patients, 27 had FLCN germline mutations. In total, 20 mutations were identified: 14 were novel mutations, including 3 splice acceptor site mutations, 2 different deletions, 6 nonsense mutations, 1 missense mutation, 1 small insertion, and 1 deletion of the whole exon 8. Conclusions: We found a similar genotype spectrum but different mutant loci in Chinese patients with BHD compared with European and American patients, thus providing stronger evidence for the clinical molecular diagnosis of BHD in China.
    [Show full text]
  • Association Between Birt Hogg Dubé Syndrome and Cancer Predisposition
    ANTICANCER RESEARCH 30: 751-758 (2010) Review Association Between Birt Hogg Dubé Syndrome and Cancer Predisposition RAFFAELE PALMIROTTA1, ANNALISA SAVONAROLA1, GIORGIA LUDOVICI1, PIETRO DONATI2, FRANCESCO CAVALIERE3, MARIA LAURA DE MARCHIS1, PATRIZIA FERRONI1 and FIORELLA GUADAGNI1 1Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele, 00165 Rome, Italy; 2Unit of Skin Histopathology, IRCCS San Gallicano Dermatologic Institute, 00144 Rome, Italy; 3Breast Unit, San Giovanni Hospital, 00184 Rome, Italy Abstract. The Birt Hogg Dubé syndrome (BHD) is a rare Clinically, the BHD syndrome exhibits numerous autosomal dominant genodermatosis predisposing patients to asymptomatic, skin colored, dome-shaped papules over the developing fibrofolliculoma, trichodiscoma and acrochordon. face, neck, and upper trunk. These lesions represent benign The syndrome is caused by germline mutations in the folliculin proliferations of the ectodermal and mesodermal components (FLCN) gene, encoding the folliculin tumor-suppressor of the pilar apparatus (2). Fibrofolliculomas are benign protein. Numerous mutations have been described in the tumors of the perifollicular connective tissue, occurring as FLCN gene, the most frequent occurring within a C8 tract of one or more yellowish dome-shaped papules, usually on the exon 11. This hypermutability is probably due to a slippage in face. Trichodiscomas are parafollicular mesenchymal DNA polymerase during replication, resulting in gains/losses hamartomas of the mesodermal portion of the hair disk, of repeat units, causing cancer predisposition. The main usually occurring as multiple small papules. Acrochordons phenotypic manifestations related to this disease are lung are small outgrowths of epidermal and dermal tissue, which cysts, leading to pneumothorax, and a 7-fold increased risk may be pedunculated, smooth or irregular, flesh-colored and for renal neoplasia, although other neoplastic manifestations benign; they usually appear as pedunculated skin tags, have been described in BHD-affected individuals.
    [Show full text]
  • Folliculin Encoded by the BHD Gene Interacts with a Binding Protein, FNIP1, and AMPK, and Is Involved in AMPK and Mtor Signaling
    Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling Masaya Baba*†, Seung-Beom Hong*†, Nirmala Sharma*, Michelle B. Warren*†, Michael L. Nickerson*‡, Akihiro Iwamatsu§, Dominic Esposito¶, William K. Gillette¶, Ralph F. Hopkins III¶, James L. Hartley¶, Mutsuo Furihataʈ, Shinya Oishi**, Wei Zhen*, Terrence R. Burke, Jr.**, W. Marston Linehan†, Laura S. Schmidt*†,††‡‡, and Berton Zbar* Laboratories of *Immunobiology and **Medicinal Chemistry, Center for Cancer Research, National Cancer Institute–Frederick, Frederick, MD 21702; ¶Protein Expression Laboratory, Research Technology Program and ††Basic Research Program, SAIC–Frederick, Inc., National Cancer Institute–Frederick, Frederick, MD 21702; ʈDepartment of Pathology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan; §Protein Research Network, Yokohama 236-0004, Japan; and †Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20894 Edited by Bert Vogelstein, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, and approved August 23, 2006 (received for review May 8, 2006) Birt–Hogg–Dube´ syndrome, a hamartoma disorder characterized BHD syndrome, also a hamartoma disorder, displays phenotypic by benign tumors of the hair follicle, lung cysts, and renal neopla- similarities to TSC that have led to speculation that BHD may sia, is caused by germ-line mutations in the BHD(FLCN) gene, which function in the pathway(s) signaling through mTOR (12, 23). To encodes a tumor-suppressor protein, folliculin (FLCN), with un- ascertain FLCN function, we searched for interacting proteins by known function. The tumor-suppressor proteins encoded by genes coimmunoprecipitation. We identified a 130-kDa FLCN- responsible for several other hamartoma syndromes, LKB1, interacting protein, FNIP1, and demonstrated its interaction with TSC1͞2, and PTEN, have been shown to be involved in the mam- AMPK, a protein important in nutrient͞energy sensing (24, 25).
    [Show full text]
  • Novel Mutations in the Folliculin Gene Associated with Spontaneous Pneumothorax
    ’ Eur Respir J 2008; 32: 1316–1320 DOI: 10.1183/09031936.00132707 CopyrightßERS Journals Ltd 2008 Novel mutations in the folliculin gene associated with spontaneous pneumothorax B.A. Fro¨hlich*, C. Zeitz#,",G.Ma´tya´s#, H. Alkadhi+, C. Tuor*, W. Berger# and E.W. Russi* ABSTRACT: Spontaneous pneumothorax is mostly sporadic but may also occur in families with AFFILIATIONS genetic disorders, such as Birt–Hogg–Dube´ syndrome, which is caused by mutations in the *Pulmonary Division, +Institute of Diagnostic Radiology, folliculin (FLCN) gene. University Hospital of Zurich, The aim of the present study was to investigate the presence and type of mutation in a Swiss #Division of Medical Molecular pedigree and in a sporadic case. Clinical examination, lung function tests and high-resolution Genetics and Gene Diagnostics, computed tomography were performed. All coding exons and flanking intronic regions of FLCN Institute of Medical Genetics, University of Zurich, Zurich, were amplified by PCR and directly sequenced. The amount of FLCN transcripts was determined Switzerland, and by quantitative real-time RT-PCR. "Institut de la Vision, INSERM U592, Two novel mutations in FLCN were identified. Three investigated family members with a history Universite´ Pierre et Marie Curie6, of at least one spontaneous pneumothorax were heterozygous for a single nucleotide substitution Paris, France. (c.779G A) that leads to a premature stop codon (p.W260X). Quantitative real-time RT-PCR CORRESPONDENCE revealed a reduction of FLCN transcripts from the patient compared with an unaffected family E.W. Russi member. DNA from the sporadic case carried a heterozygous missense mutation (c.394G.A).
    [Show full text]
  • Mitochondria Turnover and Lysosomal Function in Hematopoietic Stem Cell Metabolism
    International Journal of Molecular Sciences Review Mitochondria Turnover and Lysosomal Function in Hematopoietic Stem Cell Metabolism Makiko Mochizuki-Kashio 1, Hiroko Shiozaki 2, Toshio Suda 3,4 and Ayako Nakamura-Ishizu 1,* 1 Microanatomy and Developmental Biology, Tokyo Women’s Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan; [email protected] 2 Department of Hematology, Tokyo Women’s Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo 162-8666, Japan; [email protected] 3 Cancer Science Institute, National University of Singapore, 14 Medical Drive, MD6, Singapore 117599, Singapore; [email protected] 4 International Research Center for Medical Sciences, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto City 860-0811, Japan * Correspondence: [email protected] Abstract: Hematopoietic stem cells (HSCs) reside in a hypoxic microenvironment that enables glycolysis-fueled metabolism and reduces oxidative stress. Nonetheless, metabolic regulation in organelles such as the mitochondria and lysosomes as well as autophagic processes have been implicated as essential for the determination of HSC cell fate. This review encompasses the current understanding of anaerobic metabolism in HSCs as well as the emerging roles of mitochondrial metabolism and lysosomal regulation for hematopoietic homeostasis. Keywords: hematopoietic stem cells; ROS; mitochondria; lysosome; autophagy; folliculin Citation: Mochizuki-Kashio, M.; Shiozaki, H.; Suda, T.; Nakamura-Ishizu, A. Mitochondria 1. Introduction Turnover and Lysosomal Function in Hematopoietic cells consist of a heterogenous group of cells originating from hematopoi- Hematopoietic Stem Cell Metabolism. etic stem cells (HSCs) [1]. HSCs differentiate into multi-potent progenitor cells (MPPs) Int. J. Mol. Sci. 2021, 22, 4627.
    [Show full text]
  • Clinical Utility of Next-Generation Sequencing-Based Panel Testing Under the Universal Health Care System in Japan: a Retrospect
    Supplementary Materials Clinical utility of Next‐Generation Sequencing‐Based Panel Testing under the Universal Health Care System in Japan: A Retrospective Analysis at a Single University Hospital Chiaki Inagaki, Daichi Maeda, Kazue Hatake, Yuki Sato, Kae Hashimoto, Daisuke Sakai, Shinichi Yachida, Iwao Nonomura and Taroh Satoh Figure S1. CONSORT diagram of patients enrolled in the study. MTB; molecular tumor board. Cancers 2021, 13, 1121. https://doi.org/10.3390/cancers13051121 www.mdpi.com/journal/cancers Cancers 2021, 13, 1121 2 of 5 Figure S2. Top 20 frequent genomic alterations with the treatment recommendation. Figure S3. The operation workflow for evaluating and nominating presumed germline findings from tumor‐only sequencing panel The workflow is adapted from the proposal of the Japan Agency for Medical Research and Development (AMED) study group concerning the information transmission process in genomic medicine). APC; adenomatous polyposis coli, BRCA1; breast cancer susceptibility gene 1, BRCA2; breast cancer susceptibility gene 2, RB1; retinoblastoma 1, TP53; tumor protein P53 Cancers 2021, 13, 1121 3 of 5 Table S1. Actionable alterations according to cancer type. No. of pa‐ Level of Evidence, n (%) No. of action‐ tients with ac‐ Cancer Type Patient, n able muta‐ tionable mu‐ 1 2 3A 3B 4 Other tion, n tation, n (%) Total 168 70 (64.8) 107 9 (8.4) 6 (5.6) 6 (5.6) 44 (41.1) 17 (15.9) 25 (23.4) Colorectal 45 19 (42.4) 26 1 (3.8) 3 (11.5) 0 (0) 8 (30.8) 3 (11.5) 11 (42.3) Sarcoma 22 8 (36.4) 16 1 (6.3) 1 (6.3) 1 (6.3) 11 (68.8)
    [Show full text]
  • “Sugar” Tumor of the Lung in a Patient with Birt-Hogg-Dubé Syndrome
    Gunji-Niitsu et al. BMC Medical Genetics (2016) 17:85 DOI 10.1186/s12881-016-0350-y CASEREPORT Open Access Benign clear cell “sugar” tumor of the lung in a patient with Birt-Hogg-Dubé syndrome: a case report Yoko Gunji-Niitsu1,8, Toshio Kumasaka2,8, Shigehiro Kitamura3, Yoshito Hoshika1,8, Takuo Hayashi4,8, Hitoshi Tokuda5, Riichiro Morita6, Etsuko Kobayashi1,8, Keiko Mitani4,8, Mika Kikkawa7, Kazuhisa Takahashi1 and Kuniaki Seyama1,8* Abstract Background: Birt-Hogg-Dubé (BHD) syndrome is a rare inherited autosomal genodermatosis and caused by germline mutation of the folliculin (FLCN) gene, a tumor suppressor gene of which protein product is involved in mechanistic target of rapamycin (mTOR) signaling pathway regulating cell growth and metabolism. Clinical manifestations in BHD syndrome is characterized by fibrofolliculomas of the skin, pulmonary cysts with or without spontaneous pneumothorax, and renal neoplasms. There has been no pulmonary neoplasm reported in BHD syndrome, although the condition is due to deleterious sequence variants in a tumor suppressor gene. Here we report, for the first time to our knowledge, a patient with BHD syndrome who was complicated with a clear cell “sugar” tumor (CCST) of the lung, a benign tumor belonging to perivascular epithelioid cell tumors (PEComas) with frequent causative relation to tuberous sclerosis complex 1 (TSC1)or2 (TSC2) gene. Case presentation: In a 38-year-old Asian woman, two well-circumscribed nodules in the left lung and multiple thin-walled, irregularly shaped cysts on the basal and medial area of the lungs were disclosed by chest roentgenogram and computer-assisted tomography (CT) during a preoperative survey for a bilateral faucial tonsillectomy.
    [Show full text]
  • Cross-Strand Binding of TFAM to a Single Mtdna Molecule Forms the Mitochondrial Nucleoid
    Cross-strand binding of TFAM to a single mtDNA molecule forms the mitochondrial nucleoid Christian Kukata,b,1, Karen M. Daviesc,1, Christian A. Wurmd,1, Henrik Spåhra, Nina A. Bonekampa, Inge Kühla, Friederike Joosc, Paola Loguercio Polosae, Chan Bae Parka,f, Viktor Posseg, Maria Falkenbergg, Stefan Jakobsd,h, Werner Kühlbrandtc, and Nils-Göran Larssona,i,2 aDepartment of Mitochondrial Biology, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany; bFACS & Imaging Core Facility, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany; cDepartment of Structural Biology, Max Planck Institute of Biophysics, 60438 Frankfurt am Main, Germany; dDepartment of NanoBiophotonics, Max Planck Institute for Biophysical Chemistry, 37077 Göttingen, Germany; eDepartment of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari Aldo Moro, 70125 Bari, Italy; fInstitute for Medical Sciences, Ajou University School of Medicine, Suwon 443-721, Korea; gDepartment of Medical Biochemistry and Cell Biology, University of Gothenburg, 405 30 Gothenburg, Sweden; hDepartment of Neurology, University of Göttingen Medical School, 37073 Göttingen, Germany; and iDepartment of Laboratory Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden Edited by F. Ulrich Hartl, Max Planck Institute of Biochemistry, Martinsried, Germany, and approved August 4, 2015 (received for review June 23, 2015) Mammalian mitochondrial DNA (mtDNA) is packaged by mito- To date, mitochondrial transcription factor A (TFAM) is the chondrial transcription factor A (TFAM) into mitochondrial nucle- only protein that fulfills a stringent definition of a structural oids that are of key importance in controlling the transmission and component that packages mtDNA in the mammalian nucleoid expression of mtDNA. Nucleoid ultrastructure is poorly defined, (8).
    [Show full text]